Alfred I. Neugut
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (14)
Background In 2004, researchers in the United Kingdom were able to train six dogs to distinguish between urine samples from bladder cancer patients and healthy controls using smell, achieving a detection rate of 41% (95% confidence interval [CI]: 23-58%), far above the 14% expected by chance. After numerous subsequent studies validated that the odor of breath and urine samples could be used by dogs to detect cancer, researchers pivoted to electronic noses (eNoses), sensor-based systems that mimic the sense of smell using arrays of chemical detectors. In this study, we review the potential efficacy of eNoses in the detection of selected cancer types in human biological samples. Methods We identified and performed a meta-analysis on 37 studies of eNose technology, comprising 1 365 cancer patients and 2 249 control subjects. We calculated the pooled sensitivity and specificity stratified by cancer type, sample type, and sensor type. Meta-regressions were conducted on these variables as well as the number of sensors used in the sensor array. Results All six cancer types analyzed—breast, colorectal, gastric, lung, ovarian, and prostate—achieved pooled sensitivities and specificities above 70%, with most around 85%. The overall pooled sensitivity was 85.9% (95% CI: 82.3-88.9%) and specificity was 83.6% (95% CI: 78.6-87.7%). Meta-regression revealed that the number of sensors in the sensor arrays, up to 15 sensors, was predictive of sensitivity with PFDR < 0.001. Conclusion This analysis found that eNoses constitute a promising tool in the early detection of cancer. However, more research is necessary before it can be introduced into clinical settings.
Year:
2026
Summary of enrollment for the N of 1 trial to date, including numbers by cancer type, the attempt to develop a PDX, establishment of PDX, RNASeq/VIPER profiling of PDX when established, and completion of drug testing.
Year:
2025
Comprehensive list of clinically relevant drugs screened in cell lines (not all were available at time of study). The list is divided into three sections, including one with FDA approved antineoplastics, one with experimental antineoplastics in clinical trials, and one with non-antineoplastics and tool compounds selectively screened when demonstrating an EC50
Year:
2025
Detailed summary of therapeutic response at end-of-study time point, organized by study group—OncoTreat, OncoTarget, or Negative control—and then stratified by each individual drug arm. The study was underpowered for statistical analyses of therapeutic response in individual drug arms.
Year:
2025
PURPOSE Gaps in surgical oncology care (GISOC), including delayed or nonreceipt of surgery, are detrimental to cancer control. This research sought to develop a risk model for predicting GISOC in South African rectal cancer (RC) patients with localized disease. METHODS This retrospective cohort study analyzed data from an existing colorectal cancer patient registry. GISOC was defined as surgery received >62 days after diagnosis with stage I-III RC or nonreceipt of surgery for stage I-III RC. Patient demographics, comorbidity, disease staging, and neoadjuvant therapy receipt were included as covariates in the analysis. A supervised logistic regression machine learning algorithm was used to train and test an appropriate risk model, which was translated into a nomogram. Receiver operating characteristic curve analyses and AUC assessments were used to establish the nomogram's performance. RESULTS The analysis included 490 patients (training data set = 245, testing data set = 245). Overall, there were 242 patients who experienced GISOC (49.4%), of whom 33 (13.6%) did not receive surgery and 209 (86.4%) had a delay in receiving surgery. The trained risk model consisted of patient race (Indian, odds ratio [OR] = 0.24; White, OR = 0.23; v Black), comorbidity (OR = 2.29 v no comorbidity), and neoadjuvant therapy receipt (OR = 18.40 v nonreceipt). AUCs for the risk model were >0.800. CONCLUSION An accurate, setting-specific risk model and nomogram was developed for predicting GISOC in patients with RC. The nomogram can be implemented without the use of technology to identify patients at high risk for GISOC, who can then be targeted with risk-reduction interventions. The impact of the nomogram on existing surgical unit workflows requires further investigation.
Year:
2025
The identification of premalignant lesions in solid tumors such as colorectal and cervical cancer has led to the development of highly effective population-wide screening programs for these malignancies. Although precursor clinical states are not well-established for most hematologic malignancies, multiple myeloma is a notable exception. Virtually all patients with multiple myeloma first develop monoclonal gammopathy of undetermined significance (MGUS), an asymptomatic but easily detectable condition. However, broad screening for MGUS has not been adopted primarily because there is no proven intervention to delay or prevent the progression of MGUS to multiple myeloma. Furthermore, the incidence of MGUS is poorly understood; a better understanding of its epidemiology will be critical in designing appropriate screening guidelines once an effective treatment has been developed. In the current issue of Cancer Epidemiology, Biomarkers & Prevention, Ji and colleagues provide important epidemiologic insights on MGUS, including a critical discussion on how its incidence and preclinical duration vary by age and race, acknowledging that both MGUS and multiple myeloma are more common in Black than White populations. See related article by Ji et al., p. 1690
Year:
2024
Summary of enrollment for the N of 1 trial to date, including numbers by cancer type, the attempt to develop a PDX, establishment of PDX, RNASeq/VIPER profiling of PDX when established, and completion of drug testing.
Year:
2024
Detailed summary of therapeutic response at end-of-study time point, organized by study group—OncoTreat, OncoTarget, or Negative control—and then stratified by each individual drug arm. The study was underpowered for statistical analyses of therapeutic response in individual drug arms.
Year:
2024
Detailed summary of therapeutic response at end-of-study time point, organized by study group—OncoTreat, OncoTarget, or Negative control—and then stratified by each individual drug arm. The study was underpowered for statistical analyses of therapeutic response in individual drug arms.
Year:
2024
Summary of enrollment for the N of 1 trial to date, including numbers by cancer type, the attempt to develop a PDX, establishment of PDX, RNASeq/VIPER profiling of PDX when established, and completion of drug testing.
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2023
Collaborators (25)
Joseph G. Jurcic
Columbia University Irving Medical Center
Prabhjot Mundi
Assistant Professor
Columbia University Irving Medical Center
Peter Sims
Assistant Professor
Columbia University Irving Medical Center
Hanina Hibshoosh
Professor of pathology at CUIMC
Columbia University
Guy M. McKhann
Florence Irving Associate Professor of Neurological Surgery
Columbia University Irving Medical Center
Ana Tergas
Rutgers, The State Univ. of NJ
Suzanne Lentzsch
Columbia University Irving Medical Center
Kenneth Olive
Assistant Dean of Graduate Curricula and Associate Professor of Medicine
Columbia University Irving Medical Center
Guarionex Joel DeCastro
Associate Professor
Columbia University
Jason D. Wright
-
Andrew Kung
Chair
Memorial Sloan Kettering Cancer Center
Mariano Alvarez
Chief Scientific Officer
KweHealth, LLC
Gary K. Schwartz
Case Western Reserve University
Andrew Lassman
Chief, Neuro-Oncology Division
Columbia University Irving Medical Center
Dawn L. Hershman
Columbia University Irving Medical Center
Kevin Kalinsky
Emory University
Katherine Crew
Professor
Columbia University Irving Medical Center
Daniel Diolaiti
Fred Hutchinson Cancer Research Center
Michael Kluger
Professor of Surgery
NYU Langone Health
Andrea Califano
Columbia University Irving Medical Center
Eugene Douglass
Assistant Professor
University of Georgia
Catherine Shu
Columbia University Irving Medical Center
Yoshan Moodley
Stellenbosch University
Melissa K. Accordino
Columbia University
Jeffrey Bruce
NewYork-Presbyterian Hospital/Columbia University Irving Medical Center
Make your next move.
Prepare your application
Review drafts before you send them.